EUCODIS delivers high-performance enzyme solutions for highly specific applications in biopharma, fine chemicals, cosmetics industry and others.
With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions.
EUCODIS Bioscience provides customized services in recombinant protein and enzyme production by covering the whole spectrum of bioprocess development up to industrial-scale manufacture of your target proteins under ISO9001.
Novel Enzymatic, 1-Step Site-Specific Protein Conjugation Technology for ADC Production
Berlin, Germany, and Vienna, Austria, April 19th: ProBioGen, a leading specialist for contract development and manufacturing of complex glycoproteins and Eucodis Bioscience, an expert in enzyme engineering, today jointly announced the signature of an exclusive license agreement on C-LiNK (CTAT), an innovative, site-specific ADC conjugation technology. Under the agreement ProBioGen gains exclusive rights to commercialize Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.